Quanterix (NASDAQ:QTRX) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Quanterix (NASDAQ:QTRX) announced its quarterly earnings results on Monday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.13), Zacks reports. Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. Quanterix updated its FY 2025 guidance to EPS.

Quanterix Stock Performance

QTRX stock traded up $0.18 during mid-day trading on Monday, hitting $5.12. The company had a trading volume of 373,037 shares, compared to its average volume of 719,550. The stock’s fifty day moving average price is $5.32 and its two-hundred day moving average price is $5.48. Quanterix has a 12 month low of $4.05 and a 12 month high of $15.67. The firm has a market cap of $237.79 million, a PE ratio of -2.81 and a beta of 1.12.

Wall Street Analysts Forecast Growth

QTRX has been the topic of a number of recent research reports. Canaccord Genuity Group restated a “hold” rating and issued a $5.00 target price (down previously from $12.00) on shares of Quanterix in a report on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Quanterix currently has a consensus rating of “Hold” and a consensus target price of $11.75.

Institutional Trading of Quanterix

Several hedge funds have recently made changes to their positions in QTRX. Balyasny Asset Management L.P. grew its stake in shares of Quanterix by 1,625.2% during the 2nd quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company’s stock worth $5,106,000 after acquiring an additional 723,295 shares during the period. Ameriprise Financial Inc. raised its position in shares of Quanterix by 14.0% in the second quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after purchasing an additional 521,639 shares during the period. Marshall Wace LLP purchased a new stake in shares of Quanterix during the 2nd quarter valued at approximately $2,954,000. Vanguard Group Inc. lifted its stake in shares of Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock valued at $14,376,000 after buying an additional 118,565 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Quanterix by 140.0% in the 2nd quarter. Jane Street Group LLC now owns 139,964 shares of the company’s stock worth $931,000 after buying an additional 81,651 shares during the period. 86.48% of the stock is currently owned by institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.